The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer

Eiki Ichihara, Daijiro Harada, Koji Inoue, Ken Sato, Shinobu Hosokawa, Daizo Kishino, Kazuhiko Watanabe, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

Research output: Contribution to journalArticle

Abstract

Objectives: : Body mass index (BMI) is reported to be associated with the efficacy of immune checkpoint inhibitors (ICIs) in solid tumors such as melanomas. However, it remains unclear whether such a relationship exists in non-small cell lung cancer (NSCLC) treated with programmed cell death protein 1 (PD-1)/ programmed death-ligand 1(PD-L1) inhibitors. The purpose of this study was to investigate the relationship between BMI and the efficacy of ICI treatment in patients with advanced NSCLC. Materials and methods: : The medical records of NSCLC patients who received PD-1/PD-L1 antibody monotherapy at nine institutions between December 2015 and May 2018 were reviewed retrospectively. The effect of BMI was investigated in two cohorts. Cohort 1 included patients with NSCLCs with high PD-L1 expression (≥ 50 %) treated with pembrolizumab as first-line therapy, and cohort 2 included patients with NSCLCs treated with nivolumab/pembrolizumab/atezolizumab as second- or later-line treatment. Results: : A total of 513 from nine institutions were analyzed (84 in cohort 1, 429 in cohort 2). Using a BMI cut-off value of 22 kg/m2, which is an ideal BMI in our country (high BMI:22.0 and low BMI:22.0), there was no significant difference in the PFS or OS between the high and low BMI patients in cohort 1. However, in cohort 2, survival was significantly longer in patients with a high versus low BMI (PFS: 3.7 vs. 2.8 months, p = 0.036; OS: 15.4 vs. 13.5 months, p = 0.021). Conclusion: : BMI was significantly associated with the efficacy of ICIs in patients with NSCLC treated with second- or later-line PD-1/PD-L1 inhibitors in our cohort.

Original languageEnglish
Pages (from-to)140-145
Number of pages6
JournalLung Cancer
Volume139
DOIs
Publication statusPublished - Jan 2020

Fingerprint

Non-Small Cell Lung Carcinoma
Body Mass Index
Ligands
Antibodies
Programmed Cell Death 1 Receptor
Ideal Body Weight
Medical Records
Melanoma
Therapeutics
Survival

Keywords

  • Body mass index
  • Immune checkpoint inhibitor
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. / Ichihara, Eiki; Harada, Daijiro; Inoue, Koji; Sato, Ken; Hosokawa, Shinobu; Kishino, Daizo; Watanabe, Kazuhiko; Ochi, Nobuaki; Oda, Naohiro; Hara, Naofumi; Hotta, Katsuyuki; Maeda, Yoshinobu; Kiura, Katsuyuki.

In: Lung Cancer, Vol. 139, 01.2020, p. 140-145.

Research output: Contribution to journalArticle

Ichihara, E, Harada, D, Inoue, K, Sato, K, Hosokawa, S, Kishino, D, Watanabe, K, Ochi, N, Oda, N, Hara, N, Hotta, K, Maeda, Y & Kiura, K 2020, 'The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer', Lung Cancer, vol. 139, pp. 140-145. https://doi.org/10.1016/j.lungcan.2019.11.011
Ichihara, Eiki ; Harada, Daijiro ; Inoue, Koji ; Sato, Ken ; Hosokawa, Shinobu ; Kishino, Daizo ; Watanabe, Kazuhiko ; Ochi, Nobuaki ; Oda, Naohiro ; Hara, Naofumi ; Hotta, Katsuyuki ; Maeda, Yoshinobu ; Kiura, Katsuyuki. / The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. In: Lung Cancer. 2020 ; Vol. 139. pp. 140-145.
@article{1bc526b633954399b69de0a09ac48e79,
title = "The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer",
abstract = "Objectives: : Body mass index (BMI) is reported to be associated with the efficacy of immune checkpoint inhibitors (ICIs) in solid tumors such as melanomas. However, it remains unclear whether such a relationship exists in non-small cell lung cancer (NSCLC) treated with programmed cell death protein 1 (PD-1)/ programmed death-ligand 1(PD-L1) inhibitors. The purpose of this study was to investigate the relationship between BMI and the efficacy of ICI treatment in patients with advanced NSCLC. Materials and methods: : The medical records of NSCLC patients who received PD-1/PD-L1 antibody monotherapy at nine institutions between December 2015 and May 2018 were reviewed retrospectively. The effect of BMI was investigated in two cohorts. Cohort 1 included patients with NSCLCs with high PD-L1 expression (≥ 50 {\%}) treated with pembrolizumab as first-line therapy, and cohort 2 included patients with NSCLCs treated with nivolumab/pembrolizumab/atezolizumab as second- or later-line treatment. Results: : A total of 513 from nine institutions were analyzed (84 in cohort 1, 429 in cohort 2). Using a BMI cut-off value of 22 kg/m2, which is an ideal BMI in our country (high BMI:22.0 and low BMI:22.0), there was no significant difference in the PFS or OS between the high and low BMI patients in cohort 1. However, in cohort 2, survival was significantly longer in patients with a high versus low BMI (PFS: 3.7 vs. 2.8 months, p = 0.036; OS: 15.4 vs. 13.5 months, p = 0.021). Conclusion: : BMI was significantly associated with the efficacy of ICIs in patients with NSCLC treated with second- or later-line PD-1/PD-L1 inhibitors in our cohort.",
keywords = "Body mass index, Immune checkpoint inhibitor, Non-small cell lung cancer",
author = "Eiki Ichihara and Daijiro Harada and Koji Inoue and Ken Sato and Shinobu Hosokawa and Daizo Kishino and Kazuhiko Watanabe and Nobuaki Ochi and Naohiro Oda and Naofumi Hara and Katsuyuki Hotta and Yoshinobu Maeda and Katsuyuki Kiura",
year = "2020",
month = "1",
doi = "10.1016/j.lungcan.2019.11.011",
language = "English",
volume = "139",
pages = "140--145",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer

AU - Ichihara, Eiki

AU - Harada, Daijiro

AU - Inoue, Koji

AU - Sato, Ken

AU - Hosokawa, Shinobu

AU - Kishino, Daizo

AU - Watanabe, Kazuhiko

AU - Ochi, Nobuaki

AU - Oda, Naohiro

AU - Hara, Naofumi

AU - Hotta, Katsuyuki

AU - Maeda, Yoshinobu

AU - Kiura, Katsuyuki

PY - 2020/1

Y1 - 2020/1

N2 - Objectives: : Body mass index (BMI) is reported to be associated with the efficacy of immune checkpoint inhibitors (ICIs) in solid tumors such as melanomas. However, it remains unclear whether such a relationship exists in non-small cell lung cancer (NSCLC) treated with programmed cell death protein 1 (PD-1)/ programmed death-ligand 1(PD-L1) inhibitors. The purpose of this study was to investigate the relationship between BMI and the efficacy of ICI treatment in patients with advanced NSCLC. Materials and methods: : The medical records of NSCLC patients who received PD-1/PD-L1 antibody monotherapy at nine institutions between December 2015 and May 2018 were reviewed retrospectively. The effect of BMI was investigated in two cohorts. Cohort 1 included patients with NSCLCs with high PD-L1 expression (≥ 50 %) treated with pembrolizumab as first-line therapy, and cohort 2 included patients with NSCLCs treated with nivolumab/pembrolizumab/atezolizumab as second- or later-line treatment. Results: : A total of 513 from nine institutions were analyzed (84 in cohort 1, 429 in cohort 2). Using a BMI cut-off value of 22 kg/m2, which is an ideal BMI in our country (high BMI:22.0 and low BMI:22.0), there was no significant difference in the PFS or OS between the high and low BMI patients in cohort 1. However, in cohort 2, survival was significantly longer in patients with a high versus low BMI (PFS: 3.7 vs. 2.8 months, p = 0.036; OS: 15.4 vs. 13.5 months, p = 0.021). Conclusion: : BMI was significantly associated with the efficacy of ICIs in patients with NSCLC treated with second- or later-line PD-1/PD-L1 inhibitors in our cohort.

AB - Objectives: : Body mass index (BMI) is reported to be associated with the efficacy of immune checkpoint inhibitors (ICIs) in solid tumors such as melanomas. However, it remains unclear whether such a relationship exists in non-small cell lung cancer (NSCLC) treated with programmed cell death protein 1 (PD-1)/ programmed death-ligand 1(PD-L1) inhibitors. The purpose of this study was to investigate the relationship between BMI and the efficacy of ICI treatment in patients with advanced NSCLC. Materials and methods: : The medical records of NSCLC patients who received PD-1/PD-L1 antibody monotherapy at nine institutions between December 2015 and May 2018 were reviewed retrospectively. The effect of BMI was investigated in two cohorts. Cohort 1 included patients with NSCLCs with high PD-L1 expression (≥ 50 %) treated with pembrolizumab as first-line therapy, and cohort 2 included patients with NSCLCs treated with nivolumab/pembrolizumab/atezolizumab as second- or later-line treatment. Results: : A total of 513 from nine institutions were analyzed (84 in cohort 1, 429 in cohort 2). Using a BMI cut-off value of 22 kg/m2, which is an ideal BMI in our country (high BMI:22.0 and low BMI:22.0), there was no significant difference in the PFS or OS between the high and low BMI patients in cohort 1. However, in cohort 2, survival was significantly longer in patients with a high versus low BMI (PFS: 3.7 vs. 2.8 months, p = 0.036; OS: 15.4 vs. 13.5 months, p = 0.021). Conclusion: : BMI was significantly associated with the efficacy of ICIs in patients with NSCLC treated with second- or later-line PD-1/PD-L1 inhibitors in our cohort.

KW - Body mass index

KW - Immune checkpoint inhibitor

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85075561748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075561748&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2019.11.011

DO - 10.1016/j.lungcan.2019.11.011

M3 - Article

AN - SCOPUS:85075561748

VL - 139

SP - 140

EP - 145

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -